Eisai Receives Positive Opinion from CHMP on Expanded Indication for Halaven for Second-Line Treatment of Advanced Breast Cancer

Eisai announced on May 27 that its UK subsidiary Eisai Europe Limited has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding an expanded indication that would allow the earlier-line...read more